Table 2.
Status of Enrollment in Medication Therapy Management Programs among Patients with Alzheimer’s Disease and Related Dementias
| Cohort | Study Period | Non-Hispanic White n (%) | Black n (%) | Hispanic n (%) | Asian/Pacific Islander n (%) | Other n (%) |
|---|---|---|---|---|---|---|
| Total Study Sample | 2013–2014 | 48,743 (16.13) | 6,971* (17.30) | 6,162* (23.09) | 1,951* (18.25) | 739 (17.67) |
| 2016–2017 | 44,299 (14.44) | 6,014* (16.71) | 4,469* (19.83) | 1,846* (16.66) | 902* (17.78) | |
| Cohort with Diabetes | 2013–2014 | 33,687 (29.17) | 6,052* (25.44) | 5,359 (31.76) | 1,622 (26.99) | 623 (27.78) |
| 2016–2017 | 32,556 (27.69) | 5,313* (24.97) | 3,984 (28.33) | 1,595 (25.96) | 766 (29.34) | |
| Cohort with Hypertension | 2013–2014 | 48,062 (17.68) | 6,954 (17.88) | 6,121*(24.52) | 1,930 (19.68) | 732* (19.57) |
| 2016–2017 | 43,805 (15.85) | 6,002* (17.26) | 4,441* (21.21) | 1,832* (18.08) | 892* (19.85) | |
| Cohort with Hyperlipidemia | 2013–2014 | 44,058 (19.69) | 6,306* (21.38) | 5,797* (26.91) | 1,825 (21.43) | 683* (22.42) |
| 2016–2017 | 41,211 (17.35) | 5,579* (20.23) | 4,265* (23.23) | 1,763 (19.26) | 849* (21.85) |
*
Frequency distribution significantly different from non-Hispanics Whites (p < .05).